Seoul, Korea, and Hilden, Germany, July 8, 2015 — Seegene Inc. (096530.KQ), today announced that it has entered into aworldwide collaboration agreement with QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA)to develop and supply molecular diagnostic assay.
Under the terms of the agreement, Seegene will develop and manufacture multiplex infectious disease testing panels exclusively designed for QIAGEN’s real-time PCR cycler Rotor-Gene Q, member of QIAGEN’s QIAsymphony family of automated instruments, and QIAGEN will have worldwide commercialization rights to these tests.
Seegene’s Founder and CEO, Dr. Jong-Yoon Chun, added, “This is an exciting partnership that will deliver a very powerful tool providing a more comprehensive and actionable diagnosis to clinicians worldwide. QIAGEN’sIVD market leadership will also help to further grow our multiplex real-time PCR diagnostic testing footprint in disease indications that are in need of powerful new diagnostics.”
Seegene expends tremendous effort to continually develop and commercialize innovative high-multiplex PCR chemistry technologies that enable more accurate and cost-effective molecular diagnostics. MuDT™ technology provides the perfection of qPCR technology by simultaneously identifying and quantifying multiple targets in a single fluorescence channel, without melting curve analysis after amplification.
“We are very pleased to partner with Seegene and incorporate their novel and innovative proprietary technologies into our sample to insight offering for molecular diagnostic customers”, said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN. “With Seegene’s multiplex reagents enabling simultaneous and multiple detection and quantification of various target genes, QIAGEN is further broadening the menu of our QIAsymphony platform and increasing its leadership in the molecular diagnostics market.”
This is the second major global original design manufacturing (ODM) deal that Seegene has entered into. In November 2014, Seegene and Beckman Coulter inked a deal under which Seegene will manufacture reagents designed exclusively for Beckman Coulter’s new Veris MDx sample-to-answer molecular diagnostics system.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2015, QIAGEN employed approximately 4,300 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies ? ACP™, DPO™, READ™, TOCE™, and MuDT™ – are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.com or call +82 2240 5550.